Regulatory and Safety Aspects of Cell and Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

    Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

    September 21-22, 2020

    14th International Conference on Genomics & Pharmacogenomics

    Vancouver, Canada
    September 23-24, 2020

    24th European Biotechnology Congress

    Berlin, Germany
    October 19-20, 2020

    7th Asia Pacific Geriatrics and Gerontology Congress

    Tokyo, Japan
    October 23-24, 2020

    2nd International Conference on Biomarkers and Cancer Targets

    Cape Town, South Africa
    November 16-17, 2020

    International Conference on Genomics and Molecular Biology

    Lisbon, Portugal
    November 19-20, 2020

    24th European Biotechnology Congress (EBC_2020)

    London, UK
    November 23-24, 2020

    International Conference on Toxicogenomics

    Bali, Indonesia
    December 07-08, 2020

    2nd World Congress on Cell and Structural Biology

    Sydney, Australia

    Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in